Stockreport

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

Revance Therapeutics, Inc.  (RVNC) 
Last revance therapeutics, inc. earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.revance.com
PDF – Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respective [Read more]